Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | XBP1 | P17861 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL899859 | 0.96 | ESR2 (0.39) | ESR1ESR2PDE10AMEN1KMT2A | |
| SCHEMBL9608266 | 0.96 | ESR1 (0.43) | ESR1ESR2PDE10AMEN1KMT2A | |
| SCHEMBL8509615 | 0.96 | ESR1 (0.43) | ESR1ESR2PDE10AMEN1KMT2A | |
| SCHEMBL9608272 | 0.96 | ESR1 (0.43) | ESR1ESR2PDE10AMEN1KMT2A | |
| SCHEMBL902985 | 0.92 | ESR1 (0.40) | ESR1ESR2PDE10AMEN1KMT2A | |
| SCHEMBL899928 | 0.85 | ESR1 (0.38) | ESR1ESR2MEN1KMT2APOLB | |
| SCHEMBL899245 | 0.79 | MEN1 (0.33) | ESR1ESR2MEN1KMT2APOLB | |
| SCHEMBL899697 | 0.75 | NUDT1 (0.35) | — | |
| SCHEMBL899767 | 0.72 | ALOX5AP (0.55) | ESR1ESR2PDE10AMEN1KMT2A | |
| SCHEMBL9608269 | 0.71 | ESR1 (0.41) | ESR1ESR2PDE10AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9261781-B2 | Preparation of norbornane-based PAC ballasts | SUMITOMO BAKELITE CO., LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-9261781-B2 | Preparation of norbornane-based PAC ballasts | SUMITOMO BAKELITE CO., LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| EP-2622410-B1 | NORBORNANE-TYPE ARYLOL COMPOUND AND CORRESPONDING PHOTOACTIVE COMPOUND, POSITIVE-TONE PHOTOSENSITIVE RESIN COMPOSITION ENCOMPASSING THE PHOTOACTIVE COMPOUND | SUMITOMO BAKELITE CO (JP) | 2014-08-20 | — | — | EP | disclosed |
| EP-2622410-B1 | NORBORNANE-TYPE ARYLOL COMPOUND AND CORRESPONDING PHOTOACTIVE COMPOUND, POSITIVE-TONE PHOTOSENSITIVE RESIN COMPOSITION ENCOMPASSING THE PHOTOACTIVE COMPOUND | SUMITOMO BAKELITE CO (JP) | 2014-08-20 | — | — | EP | disclosed |
| US-8530133-B2 | Preparation of norbornane-based PAC ballasts | PROMERUS, LLC (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530133-B2 | Preparation of norbornane-based PAC ballasts | PROMERUS, LLC (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530133-B2 | Preparation of norbornane-based PAC ballasts | PROMERUS, LLC (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120135352-A1 | Preparation of Norbornane-based PAC Ballasts | PROMERUS LLC (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135352-A1 | Preparation of Norbornane-based PAC Ballasts | PROMERUS LLC (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135352-A1 | Preparation of Norbornane-based PAC Ballasts | PROMERUS LLC (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135352-A1 | Preparation of Norbornane-based PAC Ballasts | NBAS, PHB2, BDNF | ESR1 2990/4885ESR2 4139/4885PDE10A 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.